A STUDY TO COMPARE QUALITY OF LIFE AND SATISFACTION IN PRIMARY IMMUNODEFICIENT PATIENTS TREATED WITH SUBCUTANEOUS INJECTIONS OF GAMMANORM® 165 MG/ML ADMINISTERED WITH TWO DIFFERENT DELIVERY DEVICES: INJECTIONS USING PUMP OR RAPID PUSH: